Oriham Capsule

Introduction

Oriham Capsule 10 mg is a medication primarily used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults. It is a selective norepinephrine reuptake inhibitor (NRI) that helps increase norepinephrine levels in the brain, which is thought to be beneficial in managing symptoms of ADHD.

Uses

Atomoxetine is used for:

Treating ADHD in children aged 6 years and older.
Treating ADHD in adolescents and adults.
Managing symptoms such as inattention, hyperactivity, and impulsivity.

Brand Name	Oriham
Type	Capsule
Weight	10 mg
Generic	Atomoxetine Hydrochloride
Manufacturer	Incepta Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Atomoxetine works by selectively inhibiting the reuptake of norepinephrine, a neurotransmitter in the brain. This increases norepinephrine levels in the synaptic cleft, which is believed to help improve attention, focus, and impulse control in individuals with ADHD.

How Long Does It Take to Work?

Atomoxetine may take several weeks to show noticeable effects. Some patients may start to see improvement in symptoms within 1-2 weeks, but it often takes 4-6 weeks to achieve full therapeutic effects. The response time can vary based on individual factors and the severity of ADHD symptoms.

Absorption

Atomoxetine is well-absorbed from the gastrointestinal tract. After oral administration, it reaches peak plasma concentrations in approximately 1-2 hours. The presence of food can delay the absorption, but it does not significantly affect the overall extent of absorption.

Route of Elimination

Atomoxetine is metabolized primarily in the liver by cytochrome P450 2D6 (CYP2D6). The drug and its metabolites are excreted mainly in the urine, with a smaller amount being eliminated in the feces.

Dosage

Initial Treatment:
Children and Adolescents up to 70 kg Body Weight: Atomoxetine should be initiated at a total daily dose of approximately 0.5mg/kg and increased after a minimum of three days to a target total daily dose of approximately 1.2mg/kg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. After an additional two to four weeks, the total daily dose may be increased to a maximum of 1.4mg/kg in patients who have not achieved an optimal response. The maximum recommended total daily dose in children and adolescents is 1.4mg/kg or 100mg, whichever is less.

Children and Adolescents over 70 kg Body Weight and Adults: Atomoxetine should be initiated at a total daily dose of 40mg and increased after a minimum of three days to a target total daily dose of approximately 80mg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. After an additional two to four weeks, the dose may be increased to a maximum of 100mg in patients who have not achieved an optimal response. The maximum recommended total daily dose in children and adolescents over 70 kg is 100mg.

Maintenance/Extended Treatment: There is no evidence available from controlled trials to indicate how long the patient with ADHD should be treated with Atomoxetine. It is generally agreed, however, that pharmacological treatment of ADHD may be needed for extended periods. Nevertheless, the physician who elects to use Atomoxetine for extended periods should periodically re-evaluate the long-term usefulness of the medicine for the individual patient.

Pediatric use: The pharmacokinetics of Atomoxetine have not been evaluated in children under 6 years of age.

The dosage of Atomoxetine depends on the patient's age, weight, and individual response. For children and adolescents, the typical starting dose is 0.5 mg/kg once daily, which can be increased to 1.2 mg/kg/day if needed. For adults, the usual dose ranges from 40 mg to 100 mg per day, administered in one or two divided doses.

Administration

Atomoxetine is administered orally, usually in the form of a capsule. It can be taken with or without food. The dosage should be adjusted according to the prescribing information and the patient’s response to the medication.

Side Effects

Common side effects of Atomoxetine include:

Decreased appetite.
Abdominal pain or nausea.
Fatigue or drowsiness.
Insomnia.
Dry mouth.

Serious side effects may include cardiovascular issues, liver problems, and psychiatric effects. Patients should contact their healthcare provider if they experience any severe or unusual symptoms.

Toxicity

Symptoms of Atomoxetine toxicity may include severe gastrointestinal discomfort, drowsiness, and agitation. In case of overdose, supportive care and symptomatic treatment are recommended. Immediate medical attention is necessary if overdose symptoms occur.

Precautions

Precautions include:

Monitoring for cardiovascular symptoms, as Atomoxetine may increase heart rate and blood pressure.
Assessing liver function periodically, especially if there is a history of liver disease.
Watching for signs of mood changes or suicidal thoughts, particularly in younger patients.

Interaction

Atomoxetine may interact with other medications, particularly those that affect the CYP2D6 enzyme system. It is important to inform healthcare providers about all medications being taken to avoid potential interactions.

Disease Interaction

Use with caution in individuals with:

Cardiovascular disease or hypertension.
Liver disease, as Atomoxetine is metabolized in the liver.
Mental health disorders, due to the risk of exacerbating psychiatric symptoms.

Drug Interaction

Atomoxetine may interact with:

Other medications that affect norepinephrine levels or CYP2D6 inhibitors.
Antidepressants, especially those that affect serotonin and norepinephrine levels.
Antihypertensive drugs, due to potential effects on blood pressure.

Food Interactions

Food does not significantly affect the absorption of Atomoxetine, although taking it with food may delay the onset of action. Patients should follow their healthcare provider’s recommendations regarding food intake and medication timing.

Pregnancy Use

Atomoxetine should be used during pregnancy only if clearly needed. The potential risks and benefits should be discussed with a healthcare provider, as the drug can cross the placental barrier and may affect the fetus.

Lactation Use

Atomoxetine is excreted in breast milk. The potential risks to the breastfeeding infant should be considered. It is important to consult a healthcare provider before using Atomoxetine while breastfeeding.

Acute Overdose

In the case of an acute overdose, seek immediate medical attention. Symptoms may include severe agitation, hallucinations, seizures, or cardiovascular effects. Treatment is typically supportive and symptomatic.

Contraindication

Atomoxetine is contraindicated in patients with:

Severe cardiovascular disorders.
Significant liver impairment.
History of pheochromocytoma or narrow-angle glaucoma.

Use Direction

Atomoxetine should be used as prescribed by a healthcare provider. It is important to follow the dosage instructions carefully and to report any side effects or unusual symptoms to a healthcare provider promptly.

Storage Conditions

Store Atomoxetine at room temperature, away from moisture and heat. Keep the medication out of reach of children and adhere to the expiration date provided on the packaging.

Volume of Distribution

The volume of distribution for Atomoxetine is approximately 1.3 L/kg, indicating its distribution throughout body tissues, including the central nervous system.

Half Life

Atomoxetine has a half-life of approximately 5-21 hours, depending on individual metabolic rates and genetic factors affecting CYP2D6 enzyme activity. The variability in half-life may influence dosing schedules.

Clearance

Atomoxetine is cleared from the body primarily through hepatic metabolism and renal excretion. The clearance rate can vary based on liver function and concurrent medications that affect liver enzyme activity.

See in details version Oriham Capsule 10 mg also Oriham Capsule 10 mg in bangla